Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Common Equity (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Common Equity for 7 consecutive years, with $67.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity fell 3.37% year-over-year to $67.5 million, compared with a TTM value of $67.5 million through Dec 2025, down 3.37%, and an annual FY2025 reading of $67.5 million, down 3.37% over the prior year.
  • Common Equity was $67.5 million for Q4 2025 at aTYR PHARMA, down from $80.0 million in the prior quarter.
  • Across five years, Common Equity topped out at $117.4 million in Q3 2021 and bottomed at $40.8 million in Q2 2021.
  • Average Common Equity over 5 years is $82.6 million, with a median of $80.7 million recorded in 2024.
  • The sharpest move saw Common Equity soared 267.02% in 2021, then tumbled 34.68% in 2022.
  • Year by year, Common Equity stood at $109.1 million in 2021, then crashed by 34.68% to $71.3 million in 2022, then rose by 26.91% to $90.5 million in 2023, then dropped by 22.81% to $69.8 million in 2024, then dropped by 3.37% to $67.5 million in 2025.
  • Business Quant data shows Common Equity for ATYR at $67.5 million in Q4 2025, $80.0 million in Q3 2025, and $74.7 million in Q2 2025.